lm11a-31 and Spinal-Cord-Injuries

lm11a-31 has been researched along with Spinal-Cord-Injuries* in 2 studies

Other Studies

2 other study(ies) available for lm11a-31 and Spinal-Cord-Injuries

Article	Year
Targeting p75 neurotrophin receptors ameliorates spinal cord injury-induced detrusor sphincter dyssynergia in mice. Neurourology and urodynamics, 2018, Volume: 37, Issue:8 To determine the role of p75 neurotrophin receptor (p75. Our studies confirm highest expression of p75. Drugs targeting p75 Topics: Animals; Electromyography; Isoleucine; Lower Urinary Tract Symptoms; Mice; Morpholines; Receptor, Nerve Growth Factor; Spinal Cord Injuries; Urethra; Urinary Bladder Diseases; Urinary Bladder, Overactive	2018
Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, Jan-09, Volume: 33, Issue:2 The lack of effective therapies for spinal cord injury points to the need for identifying novel targets for therapeutic intervention. Here we report that a small molecule, LM11A-31, developed to block proNGF-p75 interaction and p75-mediated cell death crosses the blood-brain barrier efficiently when delivered orally. Administered starting 4 h postinjury, LM11A-31 promotes functional recovery without causing any toxicity or increased pain in a mouse model of spinal contusion injury. In both weight-bearing open-field tests and nonweight-bearing swim tests, LM11A-31 was effective in improving motor function and coordination. Such functional improvement correlated with a >50% increase in the number of surviving oligodendrocytes and myelinated axons. We also demonstrate that LM11A-31 indeed inhibits proNGF-p75 interaction in vivo, thereby curtailing the JNK3-mediated apoptotic cascade. These results thus highlight p75 as a novel therapeutic target for an orally delivered treatment for spinal cord injury. Topics: Animals; Blotting, Western; DNA; Dose-Response Relationship, Drug; Forelimb; Hindlimb; Hyperalgesia; Immunohistochemistry; Isoleucine; Locomotion; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Mitogen-Activated Protein Kinase 10; Morpholines; Myelin Sheath; Nerve Growth Factor; Polymerase Chain Reaction; Protein Precursors; Receptor, Nerve Growth Factor; Spinal Cord Injuries; Swimming	2013

Article

Year

Targeting p75 neurotrophin receptors ameliorates spinal cord injury-induced detrusor sphincter dyssynergia in mice.

Neurourology and urodynamics, 2018, Volume: 37, Issue:8

To determine the role of p75 neurotrophin receptor (p75. Our studies confirm highest expression of p75. Drugs targeting p75

Topics: Animals; Electromyography; Isoleucine; Lower Urinary Tract Symptoms; Mice; Morpholines; Receptor, Nerve Growth Factor; Spinal Cord Injuries; Urethra; Urinary Bladder Diseases; Urinary Bladder, Overactive

2018

Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury.

The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, Jan-09, Volume: 33, Issue:2

The lack of effective therapies for spinal cord injury points to the need for identifying novel targets for therapeutic intervention. Here we report that a small molecule, LM11A-31, developed to block proNGF-p75 interaction and p75-mediated cell death crosses the blood-brain barrier efficiently when delivered orally. Administered starting 4 h postinjury, LM11A-31 promotes functional recovery without causing any toxicity or increased pain in a mouse model of spinal contusion injury. In both weight-bearing open-field tests and nonweight-bearing swim tests, LM11A-31 was effective in improving motor function and coordination. Such functional improvement correlated with a >50% increase in the number of surviving oligodendrocytes and myelinated axons. We also demonstrate that LM11A-31 indeed inhibits proNGF-p75 interaction in vivo, thereby curtailing the JNK3-mediated apoptotic cascade. These results thus highlight p75 as a novel therapeutic target for an orally delivered treatment for spinal cord injury.

Topics: Animals; Blotting, Western; DNA; Dose-Response Relationship, Drug; Forelimb; Hindlimb; Hyperalgesia; Immunohistochemistry; Isoleucine; Locomotion; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Mitogen-Activated Protein Kinase 10; Morpholines; Myelin Sheath; Nerve Growth Factor; Polymerase Chain Reaction; Protein Precursors; Receptor, Nerve Growth Factor; Spinal Cord Injuries; Swimming

2013